Skip to main content
SpringerLink
Log in

Differential tempol effects in prostatic cancer: angiogenesis and short- and long-term treatments

  • Original Paper
  • Published:
Journal of Molecular Histology Aims and scope Submit manuscript

Abstract

Prostate cancer (PCa) is the second cause of cancer death among men worldwide. Several processes are involved in the development and progression of PCa such as angiogenesis, inflammation and oxidative stress. The present study investigated the effect of short- or long-term Tempol treatment at different stages of prostate adenocarcinoma progression, focusing on angiogenic, proliferative, and stromal remodeling processes in TRAMP mice. The dorsolateral lobe of the prostate of TRAMP mice were evaluated at two different stages of PCa progression; early and late stages. Early stage was again divided into, short- or long-term. 50 mg/kg Tempol dose was administered orally. The results demonstrated that Tempol mitigated the prostate histopathological lesion progressions in the TRAMP mice in all treated groups. However, Tempol increased molecules involved in the angiogenic process such as CD31 and VEGFR2 relative frequencies, particularly in long-term treatment. In addition, Tempol upregulated molecule levels involved in angiogenesis and stromal remodeling process VEGF, TGF-β1, VE-cadherin and vimentin, particularly, in T8-16 group. Thus, it was concluded that Tempol treatment delayed prostatic lesion progression in the dorsolateral lobe of the TRAMP mice. However, Tempol also led to pro-angiogenic effects and glandular stromal microenvironment imbalance, especially, in the long-term treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7

Similar content being viewed by others

References

  • Barron DA et al (2012) The reactive stroma microenvironment and prostate cancer progression. Endocrine-related cancer 19(6):R187–R204

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Battisti V et al (2011) Oxidative stress and antioxidant status in prostate cancer patients: relation to Gleason score, treatment and bone metastasis. Biomed Pharmacother 65(7):516–524

    Article  CAS  PubMed  Google Scholar 

  • Bavik C et al (2006) The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. Cancer Res 66(2):794–802

    Article  CAS  PubMed  Google Scholar 

  • Berman-Booty LD (2012) A review of the existing grading schemes and a proposal for a modified grading scheme for prostatic lesions in TRAMP mice. Toxicologic Pathol  10(1):5–17

    Article  Google Scholar 

  • Cardano M et al (2020) Targeting proliferating cell nuclear antigen (PCNA) as an effective strategy to inhibit tumor cell proliferation. Curr Cancer Drug Targ 20(4):240–252

    Article  CAS  Google Scholar 

  • Carmeliet P, Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473:298–307

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Condon MS (2005) The role of the stromal microenvironment in prostate cancer. Seminars in cancer biology. Academic, pp 132–137.

  • Cunha GR et al (2003) Role of the stromal microenvironment in carcinogenesis of the prostate. Prost Ren Cancer, Benign Prost Hyperplasia, Erect Dysfunct Basic Res 107(1):1–10

    CAS  Google Scholar 

  • De Nunzio C et al (2012) The correlation between metabolic syndrome and prostatic diseases. Eur Urol 61(3):560–570

    Article  CAS  PubMed  Google Scholar 

  • Gelanin DP (2009) A systematic review of human antioxidant genes. Front Bioscience-Landmark 14(12):4457–4463

    Article  Google Scholar 

  • Gianluigi TAVERNA et al (2015) Inflammation and prostate cancer: friends or foe? Inflamm Res v 64:275–286

    Article  Google Scholar 

  • Gingrich JR et al (1999) Pathologic progression of autochthonous prostate cancer in the TRAMP model. Prost Cancer Prost Dis 2(2):70–75

    Article  CAS  Google Scholar 

  • Hermes TA et al (2019) Tempol treatment shows phenotype improvement in mdx mice. PLoS One 14(4):e0215590

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hochberg DA (2002) Decreased suburethral prostatic microvessel density in finasteride treated prostates: a possible mechanism for reduced bleeding in benign prostatic hyperplasia. J Urol (4):1731–1733

    Article  CAS  PubMed  Google Scholar 

  • Huang YJ et al (2019) Oxidative stress-induced angiogenesis. J Clin Neurosci  63:13–16

    Article  CAS  PubMed  Google Scholar 

  • Huss WJ et al (2001) Angiogenesis and prostate cancer: identification of a molecular progression switch. Cancer Res 61(6):2736–2743

    CAS  PubMed  Google Scholar 

  • INCA (2023) Câncer de Próstata. Disponível . https://www.inca.gov.br/tipos-de-cancer/cancer-de-prostata. Access: May 14th

  • Isabela ROSSETTO et al (2022) Tempol differential effect on prostate cancer inflammation: In vitro and in vivo evaluation. The Prostate 83(5):403–415. https://doi.org/10.1002/pros.24473

    Article  CAS  Google Scholar 

  • Jerrold ZAR (1999) H. Biostatistical analysis. Pearson Education India

  • Junqueira LC, Carneiro J (1979) Histoquímica e Citoquímica. Histologia Básica.

  • Labanca E et al (2015) Association of HO-1 and BRCA1 Is critical for the maintenance of cellular homeostasis in prostate cancer BRCA1 activates HO-1 transcription. Mol Cancer Res 13(11):1455–1464

    Article  CAS  PubMed  Google Scholar 

  • Le Guelte, A et al (2011) Jumping the barrier: VE-cadherin, VEGF and other angiogenic modifiers in cancer. Biol Cell 103(12):593–605

    Article  CAS  PubMed  Google Scholar 

  • Malik SS et al (2018) Risk factors for prostate cancer: a multifactorial case-control study. Curr Probl Cancer  42(3):337–343

    Article  PubMed  Google Scholar 

  • Marzioni D et al (2023) NRF2 modulation in TRAMP mice: an in vivo model of prostate cancer. Mol Biology Rep  50(1):873–881

    Article  CAS  Google Scholar 

  • Melegh Z et al (2019) Targeting angiogenesis in prostate cancer. Int J Mol Sci 20(11):2676

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Montico F et al (2013) Angiogenic and tissue remodeling factors in the prostate of elderly rats submitted to hormonal replacement. The Anat Rec 296(11):1758–1767

    Article  CAS  Google Scholar 

  • Montico F et al (2015) Reactive stroma in the prostate during late life: the role of microvasculature and antiangiogenic therapy influences  The Prostate 75(14):1643–1661

    Article  CAS  PubMed  Google Scholar 

  • Nishida N et al (2006) Angiogenesis in cancer. Vasc Health Risk Manag 2(3):213–219

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Niu YN et al (2009) Stroma–epithelium crosstalk in prostate cancer. Asian J Androl  11(1):28

    Article  CAS  PubMed  Google Scholar 

  • Muscoli C et al (2003) On the selectivity of superoxide dismutase mimetics and its importance in pharmacological studies. Br J Pharmacol  140(3):445–460

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ohtake S et al (2018) Oxidative stress marker 8-hydroxyguanosine is more highly expressed in prostate cancer than in benign prostatic hyperplasia. Mol Clin Oncol 9(3):302–304

    CAS  PubMed  PubMed Central  Google Scholar 

  • Olimi AF (2000) Carcinoma-associated fibroblasts stimulate tumor progression of initiated human epithelium. Breast Cancer Res v 2:1–1

    Google Scholar 

  • Rebello R (2021) Prostate cancer. Nature reviews. Dis Prim. https://doi.org/10.1038/s41572-020-00243-0

    Article  Google Scholar 

  • Reuter S et al (2010) Oxidative stress, inflammation, and cancer: how are they linked ? Free Radic Biol Med 49(11):1603–1616

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rizzi E et al (2013) Tempol inhibits TGF-β and MMPs upregulation and prevents cardiac hypertensive changes. Int J Cardiol (1):165–173

    Article  PubMed  Google Scholar 

  • Rowley DR (1998) What might a stromal response mean to prostate cancer progression? Cancer Metastasis Rev 17:411–419

    Article  CAS  PubMed  Google Scholar 

  • Sciarra A et al (2008) Prostate growth and inflammation. J Steroid Biochem Mol Biol 108:3–5

    Article  Google Scholar 

  • Sfanos KS et al (2018) The inflammatory microenvironment and microbiome in prostate cancer development. Nat Reviews Urol 15(1):11–24

    Article  Google Scholar 

  • Shashni B et al (2021) Management of tumor growth and angiogenesis in triple-negative breast cancer by using redox nanoparticles. Biomaterials 269:120645

    Article  CAS  PubMed  Google Scholar 

  • SHULIN ARUNS, Li (2011) Vimentin as a potential molecular target in cancer therapy or vimentin, an overview and its potential as a molecular target for cancer therapy. Cell Mol Life Sci v 68:3033–3046

    Article  Google Scholar 

  • Siegel RL et al (2023) Cancer statistics. CA: a cancer journal for clinicians 68(1):7–30

    Google Scholar 

  • Silva HNM et al (2021) Oxidative stress, inflammation, and activators of mitochondrial biogenesis: Tempol targets in the diaphragm muscle of exercise trained-mdx mice. Front Physiol 12:649793

    Article  PubMed  PubMed Central  Google Scholar 

  • Thomas R et al (2012) A novel class of androgen receptor inhibitors that suppresses castration-resistant growth of prostate cancer SOD Mimetics: a novel class of AR inhibitors. Mol Cancer Ther 11(1):87–97

    Article  CAS  PubMed  Google Scholar 

  • Tomas D et al (2010) Intensity of stromal changes predicts biochemical recurrence-free survival in prostatic carcinoma. Scand J Urol Nephrol  44(5):284–290

    Article  PubMed  Google Scholar 

  • Tuxhorn JA (2002a) Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. Clin Cancer Res 8:2912–2923

    CAS  PubMed  Google Scholar 

  • Tuxhorn JA et al (2002b) Stromal cells promote angiogenesis and growth of human prostate tumors in a differential reactive stroma (DRS) xenograft model. , v. 62, n. 11. Cancer Res 62(11):3298–3307

    CAS  PubMed  Google Scholar 

  • Tuxhornja JA, Gustavo E et al (2001) Reactive stroma in prostate cancer progression.  J Urol. https://doi.org/10.1016/S0022-5347(05)65620-0

    Article  Google Scholar 

  • Van Moorselaar RJA et al (2002) Angiogenesis in prostate cancer: its role in disease progression and possible therapeutic approaches. Mol Cell Endocrinol. https://doi.org/10.1016/S0303-7207(02)00262-9

    Article  PubMed  Google Scholar 

  • Verona EV et al (2007) Transforming growth factor-β signaling in prostate stromal cells supports prostate carcinoma growth by up-regulating stromal genes related to tissue remodeling. Cancer Research 67(12):5737–5746

    Article  CAS  PubMed  Google Scholar 

  • Vestweber D (2008) VE-cadherin: the major endothelial adhesion molecule controlling cellular junctions and blood vessel formation. Arterioscler Thromb Vasc Biol 28(2):223–232

    Article  CAS  PubMed  Google Scholar 

  • Wang X et al (2020) Molecular bases of VEGFR-2-mediated physiological function and pathological role. Front Cell Dev Biol 8:599281

    Article  PubMed  PubMed Central  Google Scholar 

  • Weidner N et al (1993) Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. The Am J pathol 143(2):401

  • Wilcox CS (2010) Effects of tempol and redox-cycling nitroxides in models of oxidative stress. Pharmacol Ther 126(2):119–145

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Xi L et al (2023) New advances in the research of clinical treatment and novel anticancer agents in tumor angiogenesis. Biomed Pharmacother 163:114806

    Article  Google Scholar 

  • Yeo C et al (2019) Serum promotes vasculogenic mimicry through the EphA2/VE-cadherin/AKT pathway in PC-3 human prostate cancer cells. Life Sci 221:267–273

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

Thanks the Multidisciplinary Center for Biological Investigation on Laboratory Animal Science (CEMIB)/UNICAMP.

Funding

This study was supported by the Coordination for the improvement of higher Education Personnel – Brasil (CAPES) – Finance Code 001 and São Paulo Research Foundation – FAPESP (2018/21647-6 and 2021/02108-0).

Author information

Authors and Affiliations

  1. Department of Structural and Functional Biology-Institute of Biology, State University of Campinas (UNICAMP), 255 Monteiro Lobato St, Campinas, SP, 13083-862, Brazil

    Felipe Rabelo Santos, Isabela Maria Urra Rossetto, Fabio Montico, Celina de Almeida Lamas & Valéria Helena Alves Cagnon

Authors
  1. Felipe Rabelo Santos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Isabela Maria Urra Rossetto
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Fabio Montico
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Celina de Almeida Lamas
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Valéria Helena Alves Cagnon
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

CVHA and SFR: These authors proposed the main manuscript idea and wrote the manuscript text. And also developed the experiment. RIMU: She also took part the experimental tecnics. SFR: He prepared figures. All authors reviewed the manuscript and wrote some part of the text.

Corresponding author

Correspondence to Valéria Helena Alves Cagnon.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Santos, F.R., Rossetto, I.M.U., Montico, F. et al. Differential tempol effects in prostatic cancer: angiogenesis and short- and long-term treatments. J Mol Histol (2024). https://doi.org/10.1007/s10735-024-10187-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s10735-024-10187-4

Keywords

Search

Navigation